Diacerein

Generic Name: Diacerein

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₂O_₈

CAS Number: 13739-02-1

Unique Ingredient Identifier: 4HU6J11EL5

Background: Diacerein is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea . Diacerein is under investigation for the treatment of Insulin Resistance, Diabetes Mellitus (Type 2), and Diabetes-Related Complications.

Indication: For the treatment of osteoarthritis affecting the hip or knee .

Associated Conditions: Osteoarthritis in the Hip Joint, Osteoarthritis of the Knee

Associated Therapies: -

Clinical Trials

Study Design of the Diacerein in Patients With Covid-19

Phase 2

Conditions: COVID-19

Interventions: Drug: placebo capsules
Drug: Diacerein

First Posted Date: 2022-02-07

Last Posted Date: 2022-08-02

Lead Sponsor: University of Campinas, Brazil

Target Recruit Count: 40

Registration Number: NCT05226754

Locations: 🇧🇷
Unicamp Clinical Hospital, Campinas, São Paulo, Brazil
🇧🇷
Hospital Estadual Sumaré, Sumaré, São Paulo, Brazil

Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients

Completed

Conditions: Ocular Surface Disease
Diacerein
Osteoarthritis

Interventions: Drug: Diacerein

First Posted Date: 2020-04-17

Last Posted Date: 2021-08-10

Lead Sponsor: Chulalongkorn University

Target Recruit Count: 34

Registration Number: NCT04351100

Locations: 🇹🇭
Faculty of medicine, Chulalongkorn university, Bangkok, Thailand

Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered in Patients With Knee OA

Phase 4

Conditions: Knee Osteoarthritis

Interventions: Drug: Diacerein
Drug: Celecoxib

First Posted Date: 2018-01-19

Last Posted Date: 2018-02-26

Lead Sponsor: Whan-Seok Choi

Target Recruit Count: 90

Registration Number: NCT03404479

Locations: 🇰🇷
Seoul ST. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin

Phase 2

Completed

Conditions: Complications of Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Diacerein

First Posted Date: 2017-07-05

Last Posted Date: 2017-07-05

Lead Sponsor: ANS Pharma

Target Recruit Count: 40

Registration Number: NCT03208309

Locations: 🇧🇷
Universidade Estadual de Feira de Santana, Feira de Santana, Bahia, Brazil
🇧🇷
Universidade Estadual de Campinas, Campinas, São Paulo, Brazil
🇧🇷
Centro de Estudos em Diabetes e Hipertensão, Fortaleza, Ceará, Brazil

Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis

Phase 3

Completed

Conditions: Osteoarthritis
Osteoarthritis, Knee

Interventions: Drug: Celecoxib
Drug: Diacerein
Drug: Placebo

First Posted Date: 2016-02-23

Last Posted Date: 2023-12-01

Lead Sponsor: TRB Chemedica International SA

Target Recruit Count: 380

Registration Number: NCT02688400

Locations: 🇨🇿
Affidea Praha, s.r.o., Prague, Czechia
🇪🇸
Rheumatology Hospital Universitario A Coruna, A Coruna, Spain
🇧🇪
Institut Médical Spécialisé - Centre DISCCA, Hornu, Belgium

and more 19 locations

Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Non-alcoholic Fatty Liver Disease

Interventions: Drug: Diacerein
Drug: Placebo

First Posted Date: 2014-09-16

Last Posted Date: 2018-05-03

Lead Sponsor: Universidade Federal do Rio de Janeiro

Target Recruit Count: 84

Registration Number: NCT02242149

Locations: 🇧🇷
Program of Arterial Hypertension, University Hospital Clementino Fraga Filho, Rio de Janeiro, Brazil

Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin

Phase 2

Conditions: Insulin Resistance
Diabetes Mellitus, Type 2
Diabetes-Related Complications

Interventions: Drug: Placebo
Drug: Diacerein

First Posted Date: 2014-06-27

Last Posted Date: 2015-09-17

Lead Sponsor: University of Campinas, Brazil

Target Recruit Count: 60

Registration Number: NCT02177643

Locations: 🇧🇷
Universidade Estadual de Feira de Santana, Feira de Santana, Bahia, Brazil
🇧🇷
Universidade Estadual de Campinas, Campinas, São Paulo, Brazil
🇧🇷
Centro de Estudos em Diabetes e Hipertensão, Fortaleza, Ceará, Brazil

Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels

Phase 4

Completed

Conditions: Primary Gout

Interventions: Drug: Febuxostat
Drug: Diacerein
Drug: Colchicine

First Posted Date: 2014-02-12

Last Posted Date: 2014-05-08

Lead Sponsor: Tongji Hospital

Target Recruit Count: 96

Registration Number: NCT02060552

Locations: 🇨🇳
Yikai YU, Wuhan, Hubei, China

Clinical Efficacy of Glucosamine Plus Diacerein Versus Mono-therapy of Glucosamine

Phase 4

Completed

Conditions: Diacerein
Osteoarthritis
Glucosamine

Interventions: Drug: Glucosamine sulfate
Drug: Placebo (for Diacerein)
Drug: Diacerein

First Posted Date: 2013-07-24

Last Posted Date: 2017-05-30

Lead Sponsor: Ramathibodi Hospital

Target Recruit Count: 148

Registration Number: NCT01906801

Locations: 🇹🇭
Department of Orthopaedics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Mahidol University, Bangkok, Thailand

Diacerein on Insulin Secretion in Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus
Overweight
Obesity

Interventions: Other: Placebo
Drug: Diacerein

First Posted Date: 2011-02-18

Last Posted Date: 2011-02-18

Lead Sponsor: Coordinación de Investigación en Salud, Mexico

Registration Number: NCT01298882

Locations: 🇲🇽
Unidad de Investigación Médica en Epidemiología Clínica, Guadalajara, Jalisco, Mexico

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy